Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CME Group Inc. SEC filings document the financial results, governance matters and market-infrastructure disclosures of a derivatives exchange and clearing operator. Form 8-K reports cover quarterly and annual results, GAAP and non-GAAP measures, pricing disclosures, material agreements and other events tied to the company’s trading, clearing, benchmark and market data activities.
The filings also describe clearing-house liquidity arrangements, including amendments to a multi-currency secured credit facility used for temporary liquidity needs related to clearing obligations and collateral mechanics. Proxy materials cover executive compensation, pay-versus-performance data, shareholder voting matters and governance. Other event reports have addressed officer transition disclosures and legal matters involving CME Group and the Board of Trade of the City of Chicago.
Lockett Phyllis M reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Phyllis M. Lockett received an equity award of 645 shares of Class A common stock on June 25, 2026. The award was granted at $225.00 per share as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.
These shares are fully vested and not subject to any vesting conditions, meaning Lockett has immediate ownership rights. Following this grant, she directly holds 4,285 shares of CME Group Class A common stock, reflecting routine, compensation-related share ownership rather than an open-market purchase or sale.
Kaye Daniel G reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Daniel G. Kaye received a grant of 645 shares of Class A common stock on June 25, 2026. The award was issued at $225.00 per share as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.
These shares are fully vested and not subject to any further vesting conditions. Following this grant, Kaye directly holds 4,845 Class A common shares, reflecting routine stock-based compensation rather than an open-market purchase.
Hobert William W reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director William W. Hobert reported routine equity compensation grants and an internal ownership reclassification, with no open‑market trades. On June 25, 2026, he received two Class A Common Stock awards: 422 shares as a fully vested annual equity grant and 645 shares issued at $225 per share in lieu of part of his cash retainer.
On May 1, 2026, WH Trading LLC made a pro‑rata, in‑kind distribution of 20,320 shares of Class A Common Stock to Hobert for no consideration, moving those shares from indirect to direct ownership. A separate 20.531‑share adjustment corrected prior clerical tracking errors so reported beneficial ownership aligns with actual holdings.
CME Group Inc. director Harold Eugene Ford Jr. reported receiving equity-based compensation in the form of Class A common stock. On June 25, 2026, he was granted 422 fully vested shares at $225 per share under the CME Group Director Stock Plan, as part of the annual equity compensation program for non-employee directors. On the same date, he also acquired 645 shares issued in lieu of a portion of his annual cash retainer, with the share count determined by dividing the cash retainer by the closing price on the grant date. These are compensation-related share awards, not open-market purchases or sales.
Durkin Bryan T reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Bryan T. Durkin received an equity award of 645 shares of Class A Common Stock at $225.00 per share. The shares were granted as part of CME Group’s annual equity compensation program for non-employee directors and are fully vested with no further vesting conditions. Following this grant, Durkin directly holds 43,652 Class A shares.
Cook Elizabeth A reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Elizabeth A. Cook reported an equity compensation grant and updated indirect holdings of Class A common stock. She received 645 fully vested shares of Class A common stock, issued as part of CME Group's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan, at a value of $225 per share. After this grant, an indirectly held trust account holds 18,416 shares of Class A common stock. A separate indirect holding entry shows 20 shares of Class A common stock held through a joint account.
Carey Charles P reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Charles P. Carey reported new indirect holdings of Class A common stock through trust-related awards and other entities. On June 25, 2026, a trust associated with him received 422 shares at $225 per share and another 645 shares at the same price.
Footnotes explain that 422 shares were granted as fully vested stock under the company’s annual equity compensation program for non-employee directors, and 645 shares were issued instead of part of his annual cash retainer, based on the closing share price on the grant date.
After these awards, indirect holdings shown include 6,846 shares by trust, 6,424 shares by another trust entry, 185 shares held by a firm, and a small partnership interest of 0.375 share, all reported as indirect ownership.
Bitsberger Timothy S. reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Timothy S. Bitsberger received a grant of 645 shares of Class A Common Stock valued at $225 per share. This was issued as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.
Following this award, Bitsberger directly holds 11,766 shares of CME Group Class A Common Stock. The granted shares are fully vested and are not subject to any vesting conditions, meaning he has full ownership and control of them immediately.
Benesh Kathryn reported acquisition or exercise transactions in this Form 4 filing.
CME Group Inc. director Kathryn Benesh received an equity award of 645 shares of Class A common stock at $225.00 per share. The shares were granted as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan and are fully vested with no further vesting conditions. Following this grant, she holds a total of 2,751.948 Class A shares directly.
CME Group Inc. announced a planned leadership transition in which longtime Chairman and CEO Terrence A. Duffy will become Executive Chairman and President and CFO Lynne C. Fitzpatrick will become Chief Executive Officer. The change will take effect on the later of March 1, 2027 and the filing of CME’s 2026 Form 10-K.
Duffy will remain CEO until that transition date, then serve as Executive Chairman through December 31, 2027 under a transition agreement that generally preserves his current pay and benefits while modifying certain equity and bonus terms. Fitzpatrick will continue as President and CFO until the transition and will join the Board and its Executive Committee when she becomes CEO.
Under her new employment agreement, Fitzpatrick will receive a $1.2 million base salary, with an annual bonus target of 200% of salary and a long-term incentive target of 700% of salary, plus defined severance, equity-vesting and post-employment non-compete terms.